Ultragenyx
Price & Volume
Stats
See moreOpen | $15.15 |
Previous Close | $15.48 |
Day Range | $15.04-$15.49 |
52W Range | $12.73-$39.88 |
Market Cap | $1.5B |
Shares Short | 20M |
Financials
See moreRevenue (12 Mos) | $717M |
Revenue Growth (YoY) | 28.1% |
Gross Profit (12 Mos) | -$149M |
Diluted EPS | -$5.82 |
News
See moreYahoo Finance • 21 days ago
FDA Approves Fayuvi. What Does It Mean for Ultragenyx (RARE)’s 2027 Profitability Target?
Yahoo Finance • 24 days ago
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) First-In-Disease Gene Therapy Approval For FAYUVI
Yahoo Finance • 25 days ago
Andelyn and Its Curator® Platform Achieve First FDA-Approved Commercial Gene Therapy Manufacturing Milestone Following FDA Approval of Ultragenyx's FAYUVITM to Treat Sanfilippo Syndrome Type A (MPS IIIA)
Yahoo Finance • 25 days ago
Ultragenyx wins FDA approval for pediatric gene therapy for Sanfilippo syndrome
About
CEO | Dr. Emil D. Kakkis M.D., Ph.D. |
CFO | Mr. Howard Horn |
Address | 60 Leveroni Court, Novato, CA, United States, 94949 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 1,371 |